Enfortumab Vedotin Plus Pembrolizumab in Patients With Advanced Urothelial Carcinoma and an FGFR Mutation

Opinion
Video

Key opinion leaders discuss the available data on combination enfortumab vedotin plus pembrolizumab for the treatment of patients with metastatic or locally advanced urothelial carcinoma and an FGFR mutation.

Newsletter

Stay up to date on practice-changing data in community practice.

Recent Videos
Related Content